Guilford Street Laboratories

In addition to our pioneering work in novel diagnostics, GSL provides Core Laboratory services to both industry and academia, supporting the entire clinical development pathway. We offer comprehensive biomarker services for proteins, lipids, and metabolites, featuring pre-established panels tailored for rare diseases, cardiovascular conditions, neurodegenerative disorders. Our team also specializes in bespoke assay development for novel biomarkers as needed. Reach out to our team today to discover how our biomarker services can enhance your innovation! hashtag #GSL #Biomarkers #CardiovascularDisease #Alzheimers #Parkinsons

We are thrilled to welcome Dr. Claire Leckey as the newest member of the GSL team joining us as Senior Scientist! Dr. Leckey brings extensive expertise in analytical neurochemistry, particularly in the development and validation of biomarker assays for monitoring neurodegenerative disorders. She will lead the clinical validation of our diagnostic tests in the neurodegenerative space, with a strong emphasis on our Parkinson's disease test. We are already benefiting from Claire's insights and are excited to see how her contributions will help drive our mission to deliver new game changing diagnostics to the masses! #teamupdate #gsl #guilfordstreetlabs

Front row seats to the show earlier watching Professor Kevin Mills talking through the creation of the predictive proteomic blood test for Parkinson’s disease. A great talk and some fantastic work done by the team, particularly Dr Jenny Hällqvist. The road now begins to validate and develop this test to the point of clinical adoption - stay tuned!

Great to see Prof Simon Heales giving a plenary on years of collaborative work on the use of MCFA in energy metabolism and epilepsy SSIEM 2024 Annual Symposium A rare example of going from cells -> animal model -> in human clinical trial with consistent results. Honoured to have played a role here with the animal work and continuing the exploration in to peroxisomal metabolism. Simon Eaton Mike Orford Tricia Rutherford

GSL is thrilled to announce that Dr. Wendy Heywood will be attending the BMSS & BSPR Super Meeting 2024! This event is a fantastic opportunity to engage with industry leaders and explore the latest advancements in mass spectrometry. We look forward to connecting with fellow professionals and gaining insights into the cutting-edge developments in the field. Stay tuned for updates as we dive into the latest innovations and trends! See you there! 👋 #BMSS2024 #BSPR2024 #MassSpec #GSL #Innovation #ScienceAndTechnology #Networking

A prime example here from our Academic co-founders for how target lipid analysis can provide key insights to mechanisms of neurodegenerative diseases, such as Parkinson's disease. Our NeuroLipid Panel allows for fully quantitative, targeted analysis of over 200 lipid species in CSF, blood or urine, with all major classes of lipid included. Get in touch with the team today to discuss how our NLP can enhance your research #biomarkers #lipids #parkinsonsdisease #GSL #NLP #neurodegeneration #diseasemechanisms

The GSL team is thrilled to announce that we will be attending the upcoming SSIEM 2024 Annual Symposium in Porto, Portugal! 🌍 Join us from September 3rd - 6th, 2024 as we dive into cutting-edge discussions on inherited metabolic disorders. This is an incredible opportunity to connect with experts from around the globe and explore the latest advancements in the field. We look forward to engaging with fellow professionals, sharing insights, and fostering collaborations that will help shape the future of metabolic medicine. See you in Porto! #SSIEM2024 #IEM #Biomarkers #GuilfordStreetLabs #GSLTeam

The diagnosis of Parkinson's disease is challenging, currently taking from six months up to three years. Additionally, 26% of patients are initially misdiagnosed, receiving treatment and even surgery for conditions they do not have.    GSL are working hard to bring the world's first diagnostic blood test to revolutionise the landscape of Parkinson's disease. Measuring 8 proteins and utilising state-of-the-art machine learning algorithms, we can accurately diagnose patients with PD up to 7 years before the development of symptoms.   We are currently building partnerships to bring this test to point-of-care, get in touch with the team if you are interested. #parkinsons #diagnostics #machinelearning #biomarkers

🚀 Exciting News from GSL! 🚀 We're thrilled to introduce the NeuroLipid Panel—a groundbreaking tool designed to revolutionize your lipidomics research! 🎉 Our new NeuroLipid Panel offers targeted analysis of over 200 lipids in cerebrospinal fluid (CSF), plasma, or urine, enabling precise insights into neurological and metabolic disorders. Whether you're focused on early-stage biomarker discovery, therapeutic monitoring, or cutting-edge research, this panel is your go-to resource for high-quality, reliable lipid profiling. With our comprehensive lipid analysis, researchers can now dive deeper into the complexities of lipid metabolism in the brain and beyond. This panel is not just a product; it's a leap forward in understanding the lipidome and its critical role in human health. 🔬 Why Choose the NeuroLipid Panel? - Broad lipid coverage: Analyze over 200 lipids, including major phospholipids, glycolipids and cardiolipins, providing a comprehensive view of lipid-related processes in neurological function. - Absolute quantification: Obtain precise and accurate measurements, giving you the confidence to draw meaningful conclusions from your data. - Versatility: Applicable to CSF, plasma, and urine samples, allowing for flexible and comprehensive lipidomic studies. - Reliability: Backed by GSL's cutting-edge technology and expertise, ensuring high-quality, consistent results. Unlock new possibilities in your research with the NeuroLipid Panel and take your lipidomics studies to the next level. Let's push the boundaries of science together! 💡 #Lipidomics #Neuroscience #Biomarkers #HealthcareInnovation #ResearchTools #GSL #NeuroLipidPanel

Really proud of this one, some of the first work I did during my PhD a “few” years back. Decanoic acid (C10) has been demonstrated to act through PPARg to increase mitochondial content, improve antioxidant status and has antiseizure activity (likely due to the above). But we’ve always wondered, if it’s acting through PPARg - the first P in PPAR stands for peroxisome - then does C10 alter peroxisomal metabolism in concert with its effect on the mitochondria. In short, yes. Our preliminary work here indicates a significant boost to VLCFA beta oxidation capabilities in a neural-like cell model following C10 exposure, linked to increased peroxisomal proliferation. Whilst this makes sense, it was really cool to demonstrate for the first time. It also begs the question - fatty acids to treat disorders of fatty acid metabolism? Big thanks to Vitaflo for supporting this work! Simon Heales Simon Eaton Tricia Rutherford Peter Clayton #MCFA #C10 #peroxisome #peroxisomaldisease #metabolism https://lnkd.in/eVn7PGTu